The FDA approved inavolisib for triplet combination use for treatment of PIK3CA-mutated locally advanced or metastatic ...

The objective response rate was 78.6% in the overall cohort, 76.9% in patients with a PD-L1 combined positive score (CPS) below 1, 68.8% in patients with a PD-L1 CPS of 1-9, and 100% in patients with ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.

F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

A retrospective chart review compared the difference in outcomes between Black patients and White patients with advanced RCC for 3 first-line therapies.

The Cytomegalovirus (CMV) Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus ...

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...